Business
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal second quarter ended March 31, 2026, and provided a business update.
About this update from Citius Oncology, Inc.
[{"type":"text","content":"$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR® launch progressesUp to $36.5 million in debt and equity capital securedBroad payer coverage established with no reimbursement denials83% of target accounts on formulary or in review","length":258,"tagName":"p","attribs":{}},{"type":"text","content":"CRANFORD, N.J., May 15, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal second quarter ended March 31, 2026, and provided a business update.","length":364,"tagName":"p"},{"type":"image","alt":"Citius Oncology logo (PRNewsfoto/Citius Oncology, Inc.)","displaySize":"","headline":null,"caption":"Citius Oncology logo (PRNewsfoto/Citius Oncology, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":357,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zp3Rh_eVDszG6FJ1Viq6iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTc5MA--/https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89","width":357,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/CueGH7LYKDPDt8Tdy5VZgg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTcxNw--/https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89","width":357,"height":400}},"href":"https://mma.prnewswire.com/media/2588198/Citius_Oncology_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""LYMPHIR's commercial launch gives us confidence in the trajectory ahead. In the first six months of fiscal 2026, which includes only four months of commercial sales since LYMPHIR's December 2025 launch, we generated $5.6 million in net revenue at gross margins of approximately 80%. This reflects initial orders by distributors during the first quarter, and subsequent reorders during the second quarter as we begin to see increased institutional demand for the therapy. As leading medical centers continue to add LYMPHIR to formulary and we build out our sales force, we believe we are moving through the expected transition from initial channel fill to sustained treatment-driven demand. We have achi...